A retrospective survey of patients with hereditary transthyretin-mediated (hATTR) amyloidosis treated with patisiran in real-world clinical practice in Belgium.

Jan L De Bleecker Kristl G Claeys Stéphanie DelstancheVinciane Van ParysJonathan Baets Sébastien Tilleux Gauthier Remiche

Published in: Acta neurologica Belgica (2023)

The patients with hATTR amyloidosis in Belgium have similar baseline demographics and disease characteristics to those studied in the patisiran APOLLO study and show a similar therapeutic response in the real-world, altering the expected disease progression in most patients.

Keyphrases

end stage renal disease
clinical practice
newly diagnosed
ejection fraction
chronic kidney disease
prognostic factors
peritoneal dialysis
cross sectional
patient reported outcomes